in elderly hypertensives and (ii) whether there is a lower limit of SBP and DBP below which the J-curve phenomenon appears in the treated elderly hypertensive population.
METHODS

Study population
This study used the National Health Insurance Service health examinee cohort (NHIS-HealS), which is a retrospective cohort randomly selected by the National Health Insurance Service (NHIS) to represent the South Korean population. 9, 10 Information regarding the health examination is described in Supplementary Text S1. Subjects who were aged >60 years and had received the first diagnosis of hypertension (Korean Classification of Disease [KCD] codes I10-I13) between 2003 and 2006 were selected from the NHIS-HealS data and were followed until 2013. Subjects with a diagnosis of malignancy, end-stage renal disease, or major cardiovascular diseases such as heart failure, ischemic heart disease, and stroke before the diagnosis of hypertension were excluded. During the follow-up period, subjects who had not received at least two health check-ups before cardiovascular events, or died in the same year of hypertension diagnosis were also excluded. Only subjects with prescription data for antihypertensive medication for at least a year were included in the analysis based on the assumption that these were treated hypertensive subjects. The disposition of the study cohort is presented in Figure 1 . Ultimately, the remaining 23,523 subjects were divided into three groups according to the average of the observed SBP or DBP, which was the average of BP measurements before clinical events or until the last followup: (i) average of the observed SBP < 130 mm Hg (n = 6,893), 130-140 mm Hg (n = 8,676), and ≥140 mm Hg (n = 7,954) or (ii) average of the observed DBP <80 mm Hg (n = 9,273), 80-90 mm Hg (n = 11,607), and ≥90 mm Hg (n = 2,643).
The study was approved by the Institutional Review Board of Yonsei University Health System (IRB no. 4-2016-1043 ) and complied with the declaration of Helsinki.
Definition of medication history
Five first-line antihypertensive agents were grouped into four classes based on prescription data: renin-angiotensin system blocker (RASB) including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers; betablocker (BB); dihydropyridine calcium channel blocker (CCB); and diuretics including hydrochlorothiazide, chlorthalidone, indapamide, and metolazone. Subjects with prescription data for antihypertensive agents for at least 1 year were assumed to be taking medication. The first prescription dates for aspirin and statins were compared with the dates of major cardiovascular events, and the use of aspirin or statins for primary prevention was assumed when the prescription date was earlier than the first diagnosis date of a major cardiovascular event.
BP measurement and outcome measurement
In the NHIS health examination, BP was measured in hospitals and clinics that were certified as medical health examination centers by the Korean National Health Insurance Corporation. The measurement protocol was for brachial BP after 5 minutes of rest in the sitting position. BP measurements were taken at each health examination centers and clinics by physicians using mercury sphygmomanometers or oscillometric devices. The choice of device was left to the discretion of individual examination centers, with the preferred recommendation for mercury sphygmomanometer until 2015, when the sale of mercury sphygmomanometers was banned. BP measurement was repeated if the first measurement exceeded 120/80 mm Hg. SBP <130 mm Hg rather than 120 mm Hg was defined as intensively controlled BP because measurement in the health examination cohort was not an unobserved, automated office BP (AOBP) measurement, but instead a manual office BP measurement. It has been established that SBP measured with AOBP is approximately 5-7 mm Hg lower than that measured through observed office BP measurement. 11 All BP measurements, including BP data before the index period, are used to calculate mean BP to include subjects who had fatal events within 2 years of a hypertension diagnosis.
The median follow-up duration was 9.3 years (interquartile range: 8.1-10.2, 213,276 person-years). The primary outcomes of the study were all-cause death and cardiovascular death. Cardiovascular death was defined as death from a disease of the circulatory system (KCD codes I00-I99). Cardiovascular death was further categorized as fatal myocardial infarction (MI; I21-I23), fatal hemorrhagic stroke (I60-I62), or fatal ischemic stroke (I63). Nonfatal cardiovascular events including MI, hemorrhagic stroke, ischemic stroke, and total stroke requiring hospitalization were investigated as secondary outcomes.
Statistical analysis
All continuous data are presented as mean ± SD, and categorical data are reported as numbers and percentages in each group. Socioeconomic variables were provided by the NHIS. Household income was categorized as upper 20%, middle 40%, and lower 40%. Residential areas were classified as either metropolitan city or province. The effects of mean SBP or DBP on all-cause and cardiovascular mortality were analyzed with Kaplan-Meier curves and multivariable Cox regression models, with SBP ≥140 mm Hg or DBP ≥90 mm Hg as a reference. Additionally, propensity scores were assigned using multinomial logistic regression for treatment groups based on age, sex, body mass index (BMI), smoking status, alcohol frequency, household income, residential area, and previous diagnosis of diabetes mellitus (DM). The adjustment factors selected were conventional cardiovascular risk factors and indicators of socioeconomic status, which has been shown to be a risk factor for cardiovascular disease from previous studies. [12] [13] [14] [15] Propensity scores were used as covariates in an adjusted Cox regression model. 16, 17 To minimize the confounding effect of the differences in baseline characteristics, a subgroup analysis in subjects taking aspirin or statins were also performed. To investigate the presence of a J-curve pattern, adjusted multivariable Cox regression models were used with SBP 130-140 mm Hg and DBP 80-90 mm Hg as a reference. All statistical analyses were performed with R Statistical Software (version 3.2.3; R Foundation for Statistical Computing, Vienna, Austria). All tests were two-sided, and statistical significance was defined as P < 0.05.
RESULTS
Demographic data
A total of 23,523 subjects were divided into three groups according to their mean SBP, and their demographic characteristics are shown in Table 1 . Briefly, the mean SBP ≥140 mm Hg group was likely to be older and male, with fewer BP measurements, a lower percentage of metropolitan residents, and fewer upper 20% household income earners than the other groups. Supplementary Table S1 shows demographic characteristics for each mean DBP category. Compared with the other two groups, subjects with mean DBP ≥90 mm Hg had a higher percentage of males, current smokers, and binge drinkers. They also had fewer BP measurements, metropolitan residents, the percentage with DM, and percentage with aspirin/statin prescriptions.
All-cause and cardiovascular mortality Table 2 shows the results of multivariable Cox regression analysis for mortality according to mean SBP categories in the total population. Compared to subjects with SBP ≥140 mm Hg, those with SBP 130-140 mm Hg had significantly lower rates of all-cause death (hazard ratio (HR) = 0.69, 95% confidence interval (CI) = 0.62-0.76, P < 0.001), cardiovascular death (HR = 0.61, 95% CI = 0.50-0.75, P < 0.001), fatal MI, and fatal hemorrhagic stroke. Subjects with SBP <130 mm Hg showed significantly lower rates of all-cause and cardiovascular death than those with SBP ≥140 mm Hg, but without additional lowering of all-cause and cardiovascular mortality compared to subjects with SBP 130-140 mm Hg. On the contrary, higher risk of all-cause death and cardiovascular death were observed in the SBP <130 mm Hg group than those of SBP 130-140 mm Hg group. There was significant reduction of fatal hemorrhagic stroke in the SBP <130 mm Hg group (HR = 0.47, 95% CI = 0.24-0.93, P = 0.029), but this was not significant compared with SBP 130-140 mm Hg group. Subjects with DBP 80-90 mm Hg had lower rates of all-cause death (HR = 0.64, 95% CI = 0.57-0.72, P < 0.001), cardiovascular death (HR = 0.51, 95% CI = 0.40-0.64, P < 0.001), fatal MI, fatal hemorrhagic stroke, and fatal ischemic stroke than subjects with DBP ≥90 mm Hg (Table 3 ). The DBP <80 mm Hg group did not have further lowering of risk compared to subjects with DBP 80-90 mm Hg.
Results of subgroup analysis according to SBP and DBP categories in aspirin and/or statins (n = 13,107) users are shown in Table 4 and Supplementary Table S2 , respectively. Subjects with SBP 130-140 mm Hg had a lower risk of all-cause and cardiovascular death than subjects with SBP ≥140 mm Hg. However, the SBP <130 mm Hg group did not have further risk reduction compared with the SBP ≥140 mm Hg group. Subjects with DBP 80-90 mm Hg had decreased risk of all-cause death, cardiovascular death, fatal MI, and fatal hemorrhagic stroke compared with subjects with DBP ≥90 mm Hg. The DBP <80 mm Hg group did not have further benefit compared with the DBP 80-90 mm Hg group. Tables S3 and S4 show multivariable Cox regression analyses of nonfatal MI and stroke in the total population and in aspirin and/or statin users. Subjects with SBP 130-140 mm Hg had a lower risk of MI, hemorrhagic stroke, ischemic stroke, and total stroke than subjects with SBP ≥140 mm Hg in the total population. In a subgroup analysis of aspirin and/or statin users, SBP 130-140 mm Hg showed a reduction of ischemic stroke and total stroke. There were no additional benefits with SBP <130 mm Hg for MI and stroke.
Subjects with DBP 80-90 mm Hg had a lower risk of MI and all types of stroke than subjects with DBP >90 mm Hg in the total population. Subjects with DBP <80 mm Hg had further decreased the risk of hemorrhagic stroke, ischemic stroke, and total stroke. In aspirin and/or statin users, subjects with DBP 80-90 mm Hg had benefit for ischemic stroke and total stroke compared with subjects with DBP ≥90 mm Hg. Subjects with DBP <80 mm Hg also had a lower risk of MI, ischemic stroke, and total stroke.
Analysis for the presence of J curve
For further analysis of the possibility of a J-curve pattern, additional analysis was performed. We divided subjects Data are presented as mean ± SD or N (%). Abbreviations: BB, beta-blocker; BP, blood pressure; CCB, calcium channel blocker; DBP, diastolic blood pressure; RASB, renin-angiotensin system blocker; SBP, systolic blood pressure.
into five groups according to the mean SBP: (i) <120 mm Hg (n = 1,456), (ii) 120-130 mm Hg (n = 5,437), (iii) 130-140 mm Hg (n = 8,676), (iv) 140-150 mm Hg (n = 5,484), and (v) ≥150 mm Hg (n = 2,470). The baseline characteristics of each group are described in Supplementary Table S5 . Subjects with SBP <120 and >150 mm Hg demonstrated significantly higher all-cause and cardiovascular mortality than the other groups. In multivariable Cox regression analyses for primary outcomes, subjects with SBP <120 mm Hg had a higher risk of all-cause death and cardiovascular death than the SBP 130-140 mm Hg group (Figure 3 , Supplementary  Table S6 ). Supplementary Figure 1 shows a J-curve association between mean SBP and adjusted HR of all-cause death and cardiovascular death. For DBP analysis, all subjects were divided into four groups according to mean DBP (Supplementary Table S7 Additional analyses evaluated subjects who had fatal events within a year of hypertension diagnosis (n = 25,858); some had only one health check-up. In these analyses, a significant increase in all-cause death in subjects with mean DBP <70 mm Hg (HR = 1.22, 95% CI = 1.03-1.45, P = 0.024) was observed (Supplementary Tables S9 and S10 ).
DISCUSSION
The main findings of this study were as follows. (i) SBP 130-140 mm Hg was significantly linked to lower risk of all-cause mortality, cardiovascular mortality, and fatal MI in elderly hypertensive subjects, compared with those with SBP ≥140 mm Hg. (ii) An mean DBP of <90 mm Hg was associated with a significant decrease in all-cause mortality, 18 The reason for the discrepancy between this study and that of the SPRINT may be due to the differences in the study population and ethnicity. The elderly population in the SPRINT elderly trial was older (more than 12 years) than Abbreviations: DBP, diastolic blood pressure; MI, myocardial infarction. All models were adjusted by propensity scores based on age, sex, residential area, household income, smoking status, alcohol frequency, body mass index, and history of diabetes mellitus. Abbreviations: MI, myocardial infarction; SBP, systolic blood pressure. All models were adjusted by propensity scores based on age, sex, residential area, household income, smoking status, alcohol frequency, body mass index, and history of diabetes mellitus.
those in this study. Moreover, the SPRINT elderly population had a high cardiovascular risk, with 25% having either cardiovascular disease and/or a high Framingham risk score. We assumed that risk-reduction of cardiovascular disease with lower SBP was weakened in our study because of a lower rate of all-cause and cardiovascular death than those of SPRINT. One other possible explanation is that difference in ethnicity. Prospective trials in Asian population including JATOS and VALISH trial did not show the benefit of strict BP control for cardiovascular disease. Furthermore, the association between BP and cardiovascular disease is different in Asian populations and Western populations. 19 Asians/Pacific Islanders tended to have lower heart disease death rates in all age groups than in other ethnicities. 20 Considering these studies, the discrepancy between SPRINT and our results may be due to the difference in ethnicity. Our results are supported by post hoc analysis of the VALISH study by Yano et al., in which SBP in the range between 130 and 144 mm Hg was associated with the lowest rate of cardiovascular disease and all-cause mortality and the risk of cardiovascular mortality was increased in subjects with SBP < 130 mm Hg. 21 One interesting finding from this study was the presence of the J-curve phenomenon for SBP. The findings included significant increases in all-cause and cardiovascular death in subjects with mean SBP <120 mm Hg. In a post hoc analysis of the International Verapamil-Trandolapril Study (INVEST), 22 a J-curve phenomenon was demonstrated for MI but not for fatal or nonfatal stroke. Moreover, in the post hoc analysis of the Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET), 23, 24 a J curve (nadir around 130 mm Hg) was demonstrated for total and cardiovascular mortality and coronary events, but not for fatal and nonfatal stroke. 23 The results from our study are also supported by the post hoc analysis of the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial, in which reduction of SBP below 120 mm Hg was associated with higher risk of cardiovascular morbidity and mortality than with SBP of 130-139 mm Hg. 25 Furthermore, in the China stroke primary prevention trial, the risk for first stroke event was significantly increased in participants with SBP <120 mm Hg compared to participants with SBP 120-130 mm Hg. 26 Although the J-curve phenomenon is usually prominent for DBP, 22, 27 subjects with DBP <70 mm Hg did not have increased risk in this study. We assumed that the primary endpoints in the mean DBP <70 mm Hg group were weakened because that group only included 919 subjects. Moreover, we selected subjects who had received at least two health check-ups, which resulted in the exclusion of subjects who had fatal events within a year of hypertension diagnosis. This is supported by the fact that the DBP J-curve pattern appeared in the analysis when fatal events within a year of hypertension diagnosis were included.
A mean BP of 130-140/80-89 mm Hg was associated with reduced risk of nonfatal MI and stroke. However, the association between MI and mean SBP was weakened in the subgroup analysis of aspirin and/or statin users. There may be several explanations for this finding. First, the administration of aspirin/statins, through their preventive effect against cardiovascular events, may have weakened the association between mean SBP and nonfatal MI. This is supported by fewer cardiovascular events in aspirin/statin users than in the total population. Second, there is an inherent limitation in defining nonfatal cardiovascular events based on the International Classification of Diseases 10th version (ICD-10) codes. We attempted to define nonfatal events as MI, hemorrhagic stroke, or ischemic stroke as a new major diagnosis that was associated with admission but cannot rule out the fact that many of the nonfatal events were misclassified or underestimated with our criteria.
The study has several limitations. First, the results from this study are hypothesis-generating findings that need to be validated with randomized clinical trials. Second, the role of reverse causality cannot be ruled out in this descriptive study. Third, we only included subjects who had received at least two health check-ups because we wanted to demonstrate the association between mean BP outcomes in treated, elderly hypertensive subjects. Consequently, we cannot rule out the fact that sick patients who were at high risk for cardiovascular events were excluded from analysis. Similarly, as subjects who had cardiovascular events within a year of hypertension diagnosis were excluded from the study. This was demonstrated by the fact that a J curve was demonstrated for DBP < 70 mm Hg when subjects who had events within 1 year of diagnosis of hypertension were included. Despite this, we wanted to demonstrate an association between mean BP and events that cannot be ascertained when events that develop within a year of diagnosis of hypertension are included. Fourth, there was a methodological problem in BP measurement. Health examination supported by the NHIS was performed in various hospitals and clinics. Thus, the lack of uniformity of BP measurement devices is a limitation. Lastly, as only 140 subjects in this study were over the age of 80, separate analysis for the very elderly hypertensive subjects did not show any significant results. Therefore, the results from this study cannot be generalized to the very elderly, hypertensive population.
In conclusion, in elderly hypertensive subjects without previous major cardiovascular disease, a mean BP of <140/90 mm Hg were associated with lowest all-cause and cardiovascular mortality without any further benefit with mean BP <130/80 mm Hg. However, mean SBP <120 mm Hg was associated with significant increases in all-cause and cardiovascular mortality.
SUPPLEMENTARY MATERIAL
Supplementary data are available at American Journal of Hypertension online.
